Analysts expect Atara Biotherapeutics Inc (NASDAQ:ATRA) to post ($1.29) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have issued estimates for Atara Biotherapeutics’ earnings, with the lowest EPS estimate coming in at ($1.32) and the highest estimate coming in at ($1.27). Atara Biotherapeutics reported earnings of ($1.75) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 26.3%. The firm is expected to report its next quarterly earnings results on Tuesday, February 25th.
According to Zacks, analysts expect that Atara Biotherapeutics will report full-year earnings of ($5.45) per share for the current year, with EPS estimates ranging from ($5.63) to ($5.14). For the next financial year, analysts expect that the company will report earnings of ($4.76) per share, with EPS estimates ranging from ($5.60) to ($3.09). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Atara Biotherapeutics.
Atara Biotherapeutics (NASDAQ:ATRA) last posted its earnings results on Thursday, November 7th. The biotechnology company reported ($1.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.40) by $0.09.
Several equities analysts have issued reports on ATRA shares. Mizuho set a $43.00 target price on Atara Biotherapeutics and gave the company a “buy” rating in a research note on Wednesday, September 18th. Stifel Nicolaus reiterated a “buy” rating on shares of Atara Biotherapeutics in a research note on Friday, October 25th. BidaskClub lowered Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 29th. ValuEngine upgraded Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, October 2nd. Finally, Zacks Investment Research upgraded Atara Biotherapeutics from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a research note on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $28.22.
In other news, insider Joe Newell sold 3,500 shares of the business’s stock in a transaction dated Friday, September 27th. The stock was sold at an average price of $13.51, for a total transaction of $47,285.00. Following the sale, the insider now owns 57,998 shares in the company, valued at $783,552.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.00% of the stock is currently owned by insiders.
Several hedge funds have recently modified their holdings of the company. Baupost Group LLC MA grew its stake in shares of Atara Biotherapeutics by 9.7% during the second quarter. Baupost Group LLC MA now owns 7,000,000 shares of the biotechnology company’s stock worth $140,770,000 after acquiring an additional 619,481 shares during the last quarter. Maverick Capital Ltd. grew its stake in shares of Atara Biotherapeutics by 128.6% during the third quarter. Maverick Capital Ltd. now owns 5,103,963 shares of the biotechnology company’s stock worth $72,068,000 after acquiring an additional 2,871,487 shares during the last quarter. BlackRock Inc. grew its stake in shares of Atara Biotherapeutics by 10.2% during the second quarter. BlackRock Inc. now owns 3,841,451 shares of the biotechnology company’s stock worth $77,252,000 after acquiring an additional 357,026 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Atara Biotherapeutics by 4.6% during the second quarter. Vanguard Group Inc. now owns 3,011,596 shares of the biotechnology company’s stock worth $60,563,000 after acquiring an additional 132,282 shares during the last quarter. Finally, State Street Corp grew its stake in shares of Atara Biotherapeutics by 12.5% during the third quarter. State Street Corp now owns 2,606,271 shares of the biotechnology company’s stock worth $36,801,000 after acquiring an additional 290,613 shares during the last quarter.
ATRA traded up $0.31 on Friday, hitting $13.99. The company had a trading volume of 407,532 shares, compared to its average volume of 664,994. The stock has a fifty day moving average price of $13.10 and a 200-day moving average price of $15.89. Atara Biotherapeutics has a 12-month low of $10.38 and a 12-month high of $43.93. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.56 and a current ratio of 9.56. The stock has a market capitalization of $757.57 million, a price-to-earnings ratio of -2.65 and a beta of 2.04.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Featured Story: Why does a company issue an IPO?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.